Characteristic | CS (800 mg/day) | Placebo | |
---|---|---|---|
(n=35) | (n=34) | p Value | |
Age (years) | 59.7 ± 9.4 | 64.9 ± 9.5 | 0.025 |
BMI (kg/m2) | 30.4 ± 4.6 | 31.5 ± 5.2 | 0.381 |
Women (n (%)) | 21 (60.0) | 20 (58.8) | >0.999 |
Cartilage volume (mm3) | 6347.1 ± 1815.5 | 6039.1 ± 1640.7 | 0.466 |
BML global score | 1.8 ± 2.1 | 2.2 ± 2.2 | 0.372 |
Knee swelling and effusion (n (%)) | 19 (54.3) | 22 (64.7) | 0.465 |
Synovial membrane thickness (mm) | 1.8 ± 0.55 | 1.8 ± 0.63 | 0.855 |
WOMAC total (0–2400) | 1408.3 ± 357.3 | 1345.8 ± 430.5 | 0.513 |
VAS (0–100) | 63.0 ± 15.9 | 62.3 ± 17.6 | 0.856 |
SF-36 general health (0–100) | 70.3 ± 16.5 | 72.3 ± 16.7 | 0.617 |
Baseline characteristics for the double-blind cohort (n=69). Data are expressed as mean ± SD or number of subjects (%) when appropriate.
BMI, body mass index; BML, bone marrow lesion; CS, chondroitin sulphate; SF-36, Short Form 36 General Health questionnaire; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.